Fig. 3

Galectin-3 in human tumors impedes CXCL9 induction by IFNγ. a Galectin-3 surface staining of melanoma cell line LB33-MEL. Control isotype staining is depicted in gray and galectin staining in black. b CXCL9 mRNA fold induction in LB33-MEL incubated for 4 h with IFNγ (50 ng ml⁻¹), LacNAc (5 mM), sucrose (5 mM), and/or a neutralizing anti-IFNγR1 antibody (5 μg ml⁻¹). Fold induction CXCL9 values were calculated using HPRT-1 as reference gene and with respect to IFNγ−treated condition (2^−ΔΔCt). Mean ± SD of 3–10 experiments. ***P < 0.001 **P < 0.01; Kruskal–Wallis test with Dunn’s Multiple Comparison Correction Test. c CXCL9 mRNA fold induction in LB33-MEL xenografts treated ex vivo for 6 h with IFNγ (50 ng ml⁻¹), LacNAc (10 mM), and/or different antibodies (10 μg ml⁻¹). Each point represents one tumor. Mean ± SEM of eight independent experiments. **P < 0.01 *P < 0.05; Wilcoxon matched-pairs signed rank test with Dunn’s Multiple Comparison Correction Test. d, e CXCL9 mRNA fold induction for SKBR3-Gal3GFP (d) and SKBR3-Gal3mutGFP (e) xenografts treated for 6 h ex vivo with IFNγ (50 ng ml⁻¹), LacNAc (10 mM), GM-CT-01 (100 μg ml⁻¹), and/or antibodies (10 μg ml⁻¹). Mean ± SEM of two independent experiments where pieces were pooled from 12 tumors SKBR3-Gal3GFP and 16 tumors SKBR3-Gal3mutGFP. ***P < 0.001; Wilcoxon matched-pairs signed rank test with Dunn’s Multiple Comparison Correction Test